达格列净与地塞米松在非糖尿病脑肿瘤患者术前处理中的作用
达格列净与地塞米松在非糖尿病脑肿瘤患者术前处理中作用的比较研究
The aim of the study is to compare between the role of dapagliflozin versus dexamethasone in pre-operative management of non-diabetic glioma patients on levetiracetam as anti-seizure drug.
研究概览
地位
条件
详细说明
- This is a randomized, parallel, and controlled study, which will be conducted on pre-operative non-diabetic glioma patients on levetiracetam as anti-seizure drug. * This study will be conducted pending registration at ClinicalTrials.gov.
- All patients will give their written informed consents.
- Data of patients will be confidential.
- Any unexpected risk will be reported to patients and Ethical Committee on time. * Randomization will be carried out based on days on hospital admission.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Tanta、埃及
- Faculty of pharmacy Tanta university
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Males & females.
-
Age: between 18 and 75 years old.
-
Pre-operative non-diabetic glioma patients on levetiracetam. • Diagnosis will be confirmed by:
- The initial clinical examination.
- Magnetic resonance imaging of the brain (MRI) with contrast.
Exclusion Criteria:
- Age: > 75 years old, and <18 years old.
- Breast feeding female. • Pregnant female.
- eGFR< 30 mL/minute/1.73 m2.
- Patients with diabetes mellitus.
- Patients with diabetic ketoacidosis.
- Patients with urinary tract infection.
- Dehydrated patients till normalized.
- Lower limb amputation patients.
- SGLT2 inhibitors hypersensitivity.
- Severe hepatic patients (child-plug score class-c).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:GroupⅠ(n=25) (Control group)
This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive placebo tablets once daily for 14 days pre-operative. |
Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative. |
|
实验性的:GroupII (n=25) (Dapagliflozin group)
This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive Dapagliflozin 10 mg once daily for 14 days pre-operative. |
Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative |
|
有源比较器:Group III (n=25) (Dexamethasone group)This group will include twenty-five non-diabetic glioma patien
This group will include twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors who will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative. |
Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
•对比大脑磁共振成像(MRI)。
大体时间:2周
|
2周
|
|
用于评估颅内张力的视神经鞘直径。
大体时间:2周
|
2周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
肿瘤坏死因子α(TNF-α)。
大体时间:2周
|
2周
|
|
白细胞介素-6 (IL-6)。
大体时间:2周
|
2周
|
合作者和调查者
出版物和有用的链接
一般刊物
- Takashima M, Nakamura K, Kiyohara T, Wakisaka Y, Hidaka M, Takaki H, Yamanaka K, Shibahara T, Wakisaka M, Ago T, Kitazono T. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. Commun Biol. 2022 Jul 2;5(1):653. doi: 10.1038/s42003-022-03605-4.
- Shim B, Stokum JA, Moyer M, Tsymbalyuk N, Tsymbalyuk O, Keledjian K, Ivanova S, Tosun C, Gerzanich V, Simard JM. Canagliflozin, an Inhibitor of the Na+-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia. Cells. 2023 Sep 6;12(18):2221. doi: 10.3390/cells12182221.
- Saeedi S, Rezayi S, Keshavarz H, R Niakan Kalhori S. MRI-based brain tumor detection using convolutional deep learning methods and chosen machine learning techniques. BMC Med Inform Decis Mak. 2023 Jan 23;23(1):16. doi: 10.1186/s12911-023-02114-6.
- Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Glioma. Nat Rev Dis Primers. 2024 May 9;10(1):33. doi: 10.1038/s41572-024-00516-y.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.